Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegaspargase + CHOP versus Hyper-CVAD in newly diagnosed peripheral T-cell lymphoma
ChiCTR-TRC-14004426Phase 4Completed
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jan 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of pegaspargase, cyclophosphamide, doxorubicin, vincristine, prednisone and 3 more in peripheral T-cell lymphoma (PTCL) (2 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Number and size of lesions, Blood routine examination and 8 more. Started Jan 2013; status: completed.
02
Drugs
pegaspargasecyclophosphamidedoxorubicinvincristineprednisone
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on ChiCTR-TRC-14004426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-14004426.